Primaquine Phosphate interactions
Checked as Primaquine in this data source.
Full monograph for Primaquine PhosphateCheck it against another medicine
Medicines
238 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Amisulpride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Others · Synergy | Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…3 documented mechanisms | 20 sources — open the full entry |
| Articaine Hydrochloride + Epinephrine Bitartrate | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Benzocaine + Butamben + Tetracaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 12 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Bupivacaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Bupivacaine Hydrochloride + Dextrose | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Cabozantinib | Major | Synergy | Cabozantinib can cause prolongation of the QT interval. | 7 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Ceritinib | Major | Synergy | Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Chloroquine Phosphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 15 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Crizotinib | Major | Synergy | Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 13 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Haloperidol | Major | Synergy | Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 14 sources — open the full entry |
| Hydrocortisone + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Hydroxychloroquine Sulphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Iloperidone | Major | Synergy | Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 9 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Ivabradine | Major | Synergy | Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong… | 10 sources — open the full entry |
| Ivosidenib | Major | Synergy | Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive… | 6 sources — open the full entry |
| Lefamulin Acetate | Major | Synergy | Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result… | 6 sources — open the full entry |
| Lidocaine + Adrenaline | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Lidocaine + Epinephrine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Lidocaine + Prilocaine | Major | Synergy | Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite. Coadministration with other oxidizing agents that can also induce…3 documented mechanisms | 18 sources — open the full entry |
| Lidocaine HydrochlorideInjectionSpray | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Loteprednol Etabonate + Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Mifepristone | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Moxifloxacin HydrochlorideInjectionOphthalmicTablet | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Moxifloxacin Hydrochloride + Xanthan Gum | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Nilotinib | Major | Synergy | Nilotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Ofloxacin + Clotrimazole + Beclomethasone + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 30 sources — open the full entry |
| Osimertinib | Major | Synergy | Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 5 sources — open the full entry |
| Ribociclib | Major | Synergy | Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 16 sources — open the full entry |
| Ropivacaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
Conditions
Conditions in which Primaquine Phosphate needs care, as documented in this source.
Agranulocytosis
MajorThe use of primaquine is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. Primaquine has been reported to cause hematologic toxicity such as bone marrow depression, anemia, and leukopenia. Therapy with primaquine should be administered cautiously in patients with preexisting bone marrow depression or leukopenia. Since large doses of primaquine may increase the risk of leukopenia, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine as manifested by leukopenia, hemolytic anemia, or methemoglobinemia. Blood cell counts should be performed regularly. Primaquine therapy should be discontinued immediately if there is a sudden decrease in leukocyte count.
1 source
- "Product Information. Primaquine (primaquine)." Sanofi Winthrop Pharmaceuticals (2001):
Glucosephosphate Dehydrogenase Deficiency
MajorHemolysis, hemolytic anemia, and methemoglobinemia have been reported during use of primaquine in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or nicotinamide adenine dinucleotide (NADH)-methemoglobin reductase deficiency. Therapy with primaquine should be administered cautiously in these patients. Since large doses of primaquine may increase the risk of hemolytic reactions, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine or that have family or personal history of favism. Blood cell counts and hemoglobin determinations should be performed regularly. Primaquine therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.
1 source
- "Product Information. Primaquine (primaquine)." Sanofi Winthrop Pharmaceuticals (2001):
Therapeutic duplication
Drug classes that overlap with Primaquine Phosphate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antimalarials
The recommended maximum number of medicines in the 'antimalarials' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antimalarials' category.
Example product in the source data (US market): Coartem